HARMONi-6 Issues Persist, Lik
After listening to the updated HARMONi-6 readout at #ASCO26 many of the original issues are still holding up and may worsen over time...
Potency ≠ Durability: KRAS Inhibitors Finally Become Druggable
Our latest review from #ASCO26 explores KRAS inhibitors and why potency doesn't equal durability: https://t.co/5HBTWpGVH2 All is not what it seems. I still find it amazing what was one such an intractable target is now made druggable by a wide range of different...
Day 1 ASCO26 Trials: Real Findings, Gaps, Future Directions
Beyond the hype: some reflections on half a dozen key trials presented on Day 1 at #ASCO26... what the data actually shows, where it falls short, and what comes next: https://t.co/gCjrLDwtYp https://t.co/BRjJULU29d
20 Phase‑3 Trials Poised to Redefine Cancer Care
In the wake of the #ASCO26 data drop, we reflect on 20 key phase 3 trials which could make a significant impact. Some of these may make their competitors irrelevant if they change the standard of care: https://t.co/EGtw35EsSk https://t.co/CG0Oe4QxDg
In‑vivo CAR‑T Therapies Take Center Stage at ASGCT26
Who's putting the boat out at #ASGCT26 when it comes to in vivo CAR-T cell therapies and what to watch out for. Some surprises in store... https://t.co/8vf35LEDpt https://t.co/85AGdXBfag
Targeted Therapies Resurge; some Phase 3 Trials Risk Obsolescence
With a rapid fire raft of trial updates coming out of #esmobreast26, one thing stood out... targeted molecules are back in fashion and a few companies might be left holding the baby if their phase 3 trials have already started: https://t.co/jlKDLsecVZ...
Agents Without Moats Will Falter in Fierce Market
Pointed ironies in the SERD wars, plus ADC hype, and what really works in breast cancer... How agents with no moat, no differentiation, and no clear advantage will struggle in a tough competitive market: https://t.co/2Efcy5ItNM https://t.co/FBDM2eDJd4
FDA Slowdown Threatens AZN's SERD Lead as Roche Advances
FDA just pumped the brakes hard on AZN's camizestrant. While the SERD track is crowded and Roche is picking up speed, AZN's innovation may be derailed by regulatory conservatism: https://t.co/9eroTXv5dc https://t.co/rOJwh9iMCz
T‑cell Engagers Need Missing Design Tricks for Success
With the rise and rise of ADCs, T cell engagers have taken something of a back seat of late. What if the bigger problem is some of them may be missing a key trick? Here we highlight some design...
MicrobiomDigest’s Eagle Eye Catches Transposed
Such blatant chutzpah; reminds me of the transposed western blots and path slides @MicrobiomDigest is such an eagle eye at spotting...
Scientists Convert pMMR Tumors to Immunotherapy‑Sensitive dMMR
For anyone else fried with #AACR26 abstracts, we can now look at them from a different lens...
Crystal Ribbon Sculpture Mirrors
Amazingly I found a sculpture in San Diego which looks like crystal ribbon structures – highly appropriate for today's more sober look at the daraxonrasib data in PDAC: https://t.co/8YGGXcyM9f https://t.co/ticCbTKYuK
Top Protein Degrader Session at AACR26 Highlights Await
Excellent protein degrader session today at #AACR26. Third speaker was all Do Not Post (sorry @HartungIngo !) so some highlights from the other three speakers coming up...
PK/PD Crucial for Next-Gen ADC Development
Wonderful tour de force on ADCs by @raffcolo highlighting the importance of PK/PD going forward with new formats https://t.co/nUpBNNoVil
Prelude Tx Unveils Early-Stage KAT6A Degrader
Looking through my #aacr26 collection of posters from yesterday. Prelude Tx have a KAT6A degrader (PRT13722) in early development to compete with inhibitors: https://t.co/23zBtCX8Hs